FreeCurrencyRates.com

इंडियन आवाज़     14 Apr 2024 01:28:36      انڈین آواز

COVAXIN Booster Shown to Neutralize Both Omicron and Delta Variants of SARS-CoV-2

(Last Updated On: 12/01/2022)
  • Booster dose of vaccine, COVAXIN® (BBV152), generated robust neutralizing antibody responses against both Omicron (B.1.529) and Delta (B.1.617.2) using a live virus neutralization assay
  • 100% of test serum samples showed neutralization of the Delta variant and more than 90% of serum samples showed neutralization of the Omicron variant
  • These data add to the body of evidence that the broad-spectrum mechanism of action of a whole virus inactivated COVID-19 vaccine, like COVAXIN® (BBV152), is a viable option in this continuously evolving pandemic

Hyderabad, India, January 12, 2022 – Bharat Biotech, today announced results from a study conducted at Emory University demonstrating that sera from subjects who received a booster dose of COVAXIN® (BBV152) six months after getting a primary two-dose series of COVAXIN® (BBV152), neutralized the SARS-CoV-2 Omicron and Delta variants. Earlier studies demonstrated the neutralizing potential of COVAXIN® (BBV152) against SARS-CoV-2 Variants of Concern Alpha, Beta, Delta, Zeta and Kappa.

The study will be published on the pre-print server, medRXiv,  shortly.

Sera samples from individuals who received a booster of COVAXIN® (BBV152) were observed to be effective in neutralizing Omicron and Delta variants on a live virus neutralization assay. The neutralization activity of COVAXIN®-boosted sera was comparable to what has been observed in mRNA vaccine-boosted sera against the Omicron variant. More than 90% of all individuals boosted with COVAXIN® (BBV152) showed neutralizing antibodies. All participants received an initial two-dose schedule of COVAXIN® (BBV152) at Day 0 and Day 28.

“As the dominant COVID-19 variant throughout the world, Omicron poses a serious public health concern,” said Mehul Suthar, Ph.D., Assistant Professor, Emory Vaccine Center and who led the laboratory analysis. “Data from this preliminary analysis show individuals receiving a booster dose of COVAXIN® have a significant immune response to both the Omicron and Delta variants. These findings suggest that a booster dose has the potential to reduce disease severity and hospitalizations.”

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech said, “We are in a continuous state of innovation and product development for COVAXIN®. The positive neutralization responses against the Omicron and Delta variants, validates our hypothesis of a multi-epitope vaccine generating both humoral and cell mediated immune responses. Our goals of developing a global vaccine against COVID-19 have been achieved with the use of COVAXIN® as a universal vaccine for adults and children.”

“The global impact of Omicron shows us that the fight against COVID-19 continues, and we’re encouraged that these data demonstrate the value of COVAXIN® as a primary and booster vaccine,” said Dr. Shankar Musunuri, Chairman, CEO and Co-Founder, Ocugen, Inc. “These results show how a broad-spectrum vaccine has the potential ability to address ever-shifting public health challenges such as new variants and mutations.”

COVAXIN® is formulated uniquely such that the same dosage can be administered to adults and children alike. COVAXIN® is a ready-to-use, liquid vaccine, stored at 2 – 8°C, with 12 months shelf life and multi-dose vial policy. The same doses of vaccine can also be used for two-dose primary immunization in adults and children and for booster dose vaccinations, making it truly a universal vaccine.

About the study

In order to evaluate the effectiveness of COVAXIN® (BBV152) against the Omicron variant, Ocugen contracted with the Emory Vaccine Center (Atlanta, GA) to test human immune sera obtained from participants (n=13) in an ongoing Phase 2 clinical trial (ClinicalTrials.gov: NCT04471519). Sera was collected 28-days post booster – six months following the primary two-dose series. Each sera was tested in a neutralization assay. Following three doses, the FRNT50 geometric mean titers (GMTs) of neutralizing antibodies against the Omicron variant measured in the samples was 75, compared to 480 against the Delta variant and 706 against the vaccine strain, D614G.

PRESS RELEASE

Leave a Reply

Your email address will not be published.

خبرنامہ

PATANJALI CASE: سپریم کورٹ نے بابا رام دیو کی معافی قبول کرنے سے انکار کر دیا۔

SOCIAL MEDIA نئی دہلی: سپریم کورٹ نے بدھ (10 اپریل 2024) کو ادویات کے ...

سپریم کورٹ نے گمراہ کن اشتہارات پر پتنجلی آیوروید اور بابا رام دیو کی سرزنش کی۔

AMN / WEB DESK سپریم کورٹ نے گمراہ کن اشتہارات کے معاملے میں منگل ...

سپریم کورٹ نے ایم پی سنجے سنگھ کو ضمانت دی، ای ڈی نے مخالفت نہیں کی۔- sanjay singh

نئی دہلی: عام آدمی پارٹی کے رکن پارلیمنٹ سنجے سنگھ کو دہلی ای ...

MARQUEE

Singapore: PM urges married Singaporean couples to have babies during year of Dragon

AMN / WEB DESK Prime Minister of Singapore Lee Hsien Loong has urged married Singaporean couples to have ba ...

Himachal Pradesh receives large number of tourists for Christmas and New Year celebrations

AMN / SHIMLA All the tourist places of Himachal Pradesh are witnessing large number of tourists for the Ch ...

Indonesia offers free entry visa to Indian travelers

AMN / WEB DESK In a bid to give further boost to its tourism industry and bring a multiplier effect on the ...

MEDIA

 Sheyphali Sharan Takes Charge as PDG of PIB

AMN Senior Information Service Officer Sheyphali B Sharan today took over the charge of Principal Director ...

Noted Journalist Zafar Agha Passes Away

Journos shocked over his demise AMN / NEW DELHI Noted journalist and and the Editor-in-Chief Nation ...

RELIGION

Mata Vaishno Devi Bhawan Decorated With Imported Flowers Ahead Of Navratri Festival

AMN In Jammu, ahead of the festivl of Navratri, Katra and Mata Vaishno Devi Bhawan is decorated with import ...

Holy Relics of Lord Buddha Return to India After Exposition in Thailand

AMN The holy relics of Lord Buddha and his disciples Arahant Sariputta and Arahant Maha Moggallana has ret ...

@Powered By: Logicsart